STRM.BIO

STRM.BIO is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing a non-viral, cell-derived delivery platform for in vivo cell and gene therapies. The company utilizes megakaryocyte-derived extracellular vesicles (MVs) to target genetic payloads to bone marrow. This technology is designed to overcome traditional limitations such as immunogenicity, lack of targeting specificity, and payload capacity constraints associated with viral and synthetic delivery systems. By leveraging the innate tropism of these vesicles, the platform enables the delivery of DNA, RNA, and gene editing components, while supporting repeat dosing strategies for chronic treatment.

The company’s approach is primarily directed toward addressing rare hematological diseases, such as Fanconi anemia, as well as advancing in vivo CAR-T cell therapies. By enabling precise, scalable, and safe gene delivery directly to hematopoietic stem and progenitor cells, STRM.BIO seeks to unlock therapeutic modalities that were previously considered impractical. Supported by venture financing and government contracts, including awards from ARPA-H, the company is focused on validating its platform and advancing its pipeline toward clinical trials, aiming to create more flexible and effective treatment options for immune and blood-related disorders.